SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gufic Biosciences surges on receiving patent by EAPO

01 Dec 2020 Evaluate

Gufic Biosciences is currently trading at Rs. 119.55, up by 2.75 points or 2.35% from its previous closing of Rs. 116.80 on the BSE.

The scrip opened at Rs. 120.95 and has touched a high and low of Rs. 121.90 and Rs. 116.00 respectively. So far 42698 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 129.60 on 13-Nov-2020 and a 52 week low of Rs. 37.55 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 121.90 and Rs. 110.10 respectively. The current market cap of the company is Rs. 930.46 crore.

The promoters holding in the company stood at 65.75%, while Institutions and Non-Institutions held 8.79% and 25.46% respectively.

Gufic Biosciences has been granted patent by the Eurasian Patent office (EAPO) for its invention of ‘A Freeze Dried Parenteral Composition of Tigecycline and Process for Preparation Thereof’. Tigecycline is a tetracycline antibiotic medication used for a number of bacterial infections and is used to treat certain serious infections including community acquired pneumonia (a lung infection that developed in a person who was not in the hospital), skin infections, and infections of the abdomen.

Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Gufic Biosciences Share Price

301.30 -1.35 (-0.45%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×